Portugal Isabella, Clavijo-Salomon Maria A
Ciências Médicas, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
Centro de Investigação Translacional em Oncologia (CTO), Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
NPJ Precis Oncol. 2024 Nov 4;8(1):251. doi: 10.1038/s41698-024-00750-3.
Fumarate hydratase (FH) mutated papillary renal cell carcinoma is an aggressive variant of kidney cancer that poorly responds to conventional targeted therapies and immunotherapy. Here, we present the 10-year follow-up of a heavily pre-treated patient with several lines of therapy, achieving a remarkable complete response to anti-PD-1 rechallenge. In addition, we highlight a common immune-related adverse event of anti-PD-1, eosinophilia, as a possible biomarker of response and using TCGA data analysis, provide proof-of-concept for tumor expression of the eosinophil-related gene SIGLEC8, as a promising powerful predictor of prognosis for papillary renal cell carcinoma patients.
富马酸水合酶（FH）突变型乳头状肾细胞癌是一种侵袭性肾癌变体，对传统靶向治疗和免疫治疗反应不佳。在此，我们报告了一名经过多线治疗的患者的10年随访情况，该患者对抗PD-1再激发治疗取得了显著的完全缓解。此外，我们强调了抗PD-1常见的免疫相关不良事件嗜酸性粒细胞增多症，作为一种可能的反应生物标志物，并通过TCGA数据分析，为嗜酸性粒细胞相关基因SIGLEC8在肿瘤中的表达提供概念验证，作为乳头状肾细胞癌患者预后的一个有前景的有力预测指标。
